Interim Results

27 February 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Craven House Capital PLC

("Craven House" or the "Company")

Unaudited Interim Report for the period ended 30 November 2024

CRAVEN HOUSE CAPITAL PLC

Statement by the Investment Manager

The Company's investment portfolio comprises shareholdings in two quoted early-stage pharmaceutical companies listed in Stockholm and ongoing minority shareholdings in five private Swedish-managed businesses operating in the eCommerce and pharmaceutical sectors. These private investee companies remain at a 'pre-revenue' stage of business development and their respective valuations have been maintained at zero. The valuations of Craven's portfolio at the end of the period are as follows:

As previously disclosed, RoseMonkey Ltd (in which Craven is a 24.4% shareholder) was awarded 1,416,007,811 shares in QuiaPeg Pharma AB in the prior period. During the current period, RoseMonkey distributed a proportionate amount of those shares to Craven House. Craven House therefore received 345,505,096 shares representing 23.2% of QuiaPeg. There was no other material activity during the current period.

Desmond Holdings LtdInvestment Manager to Craven House Capital Plc

 CRAVEN HOUSE CAPITAL PLC

STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024

CRAVEN HOUSE CAPITAL PLC

STATEMENT OF FINANCIAL POSITION

 AS AT 30 NOVEMBER 2024

STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024

CRAVEN HOUSE CAPITAL PLC

STATEMENT OF CASH FLOWS

FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024

CRAVEN HOUSE CAPITAL PLC

NOTES TO THE FINANCIAL INFORMATION

FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024

1. ACCOUNTING POLICIES

General Information

Craven House Capital Plc is a company incorporated in the United Kingdom under the Companies Act 2006. The address of the registered office is given on the company information page. The Company is listed on the AIM Market of the London Stock Exchange (ticker: CRV).

The next annual financial statements of Craven House Capital Plc will be prepared in accordance with International Financial Reporting Standards and IFRIC interpretations and with those parts of the Companies Act 2006 applicable to companies reporting under UK adopted international standards. Accordingly, the interim financial information in this report has been prepared using accounting policies consistent with IFRS. IFRS are subject to amendment and interpretation by the International Accounting Standards Board (IASB) and the International Financial Reporting Interpretations Committee (IFRIC) and there is an on-going process of review and endorsement by the European Commission. The financial information has been prepared on the basis of the IFRS that the directors expect to be applicable as at 31 May 2025.

The financial information has been prepared under the historical cost convention, except to the extent varied for fair value adjustments required by accounting standards, and in accordance with International Financial Reporting Standards and IFRIC interpretations and with those parts of the Companies Act 2006 applicable to companies reporting under UK adopted international standards. The principal accounting policies have been applied to all periods presented.

This financial information is unaudited and does not constitute statutory financial statements within the meaning of Section 434 of the Companies Act 2006. The financial statements of the Company for the year ended 31 May 2024, which were prepared in accordance with International Financial Reporting Standards and IFRIC interpretations and with those parts of the Companies Act 2006 applicable to companies reporting under UK adopted international standards, have been reported on by the Company's auditors and delivered to the Registrar of Companies. The report of the auditors was unqualified and did not include any statement under Section 498 of the Companies Act 2006.

This financial information is presented in United States dollar, rounded to the nearest $'000.

The directors do not propose the issuance of a dividend.

The interim financial information for the six months ended 30 November 2024 was approved by the directors on 26 February 2025.

Going concern

The directors consider that the Company is well placed to manage its business risks successfully and have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the financial information.

CRAVEN HOUSE CAPITAL PLC

NOTES TO THE FINANCIAL INFORMATION - continued

FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024

2. Taxation

No tax charges arose in the period or in comparative periods as a result of losses incurred.

3.  Investments at fair value through profit or loss

The value of Investments represents the Company's holdings in two quoted, early-stage pharmaceutical companies, listed in Stockholm. Both of these holdings are valued on a mark-to-market basis as follows:

341,405,096 shares in Quia Pharma AB, which had a share price of EUR 0.001 as at 30 November 2024 resulting in a total valuation of USD $361,138.

4,052,046 shares in Bio Vitos Pharma AB, which had a share price of SEK 0.632 as at 30 November 2024 resulting in a total valuation of USD $235,003.

The company retains its holdings in the below-named five privately owned UK entities which are all unquoted and have therefore been measured on a Level 3 basis as no observable market data is available. Further information on each investment holding is as follows;

Shares in Garimon Limited are valued at $nil representing a 29.9% holding. Garimon Limited is the owner of "Magazinos.com", an on-line media magazine and periodical content provision service. Despite the potential future value of this investment, the fair value has been impaired to zero due to the current absence of tangible arm's length or market-based valuation metrics.

Shares in Stormfjord Limited are valued at $nil representing a 25.5% holding. Stormfjord is the owner of the domain www.onebas.com, an optimised search engine providing a portal to music content freely circulating online. Despite the potential future value of this investment, the fair value has been impaired to zero due to the current absence of tangible arm's length or market-based valuation metrics.

CRAVEN HOUSE CAPITAL PLC

NOTES TO THE FINANCIAL INFORMATION - continued

FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024

CRAVEN HOUSE CAPITAL PLC

NOTES TO THE FINANCIAL INFORMATION - continued

FOR THE SIX MONTH PERIOD ENDED 30 NOVEMBER 2024

The calculation of basic earnings per share is based on the loss attributable to the equity holders of $2,000 divided by the weighted average number of shares in issue during the period of 3,863,590 (six months ended 30 November 2023: loss of $114,000 and 3,863,590 shares; year ended 31 May 2024: loss of $893,000 and 3,863,590 shares).

6.  Related party disclosures

Craven Industrial Holdings Plc

At the period end, the outstanding balance due to Craven Industrial Holdings Plc was $1,622,000. Despite the common director in Mr M J Pajak, the board of Craven House Capital Plc do not believe that Craven House Capital Plc or Craven Industrial Holdings Plc are able to exert control or influence over each other and neither are accustomed to act in accordance with instructions from the other.

7. Events after the reporting period

 None.

For further information please contact:

 About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.